Clay Siegall

President and CEO at Immunome
Greater Seattle Area

Clay Siegall is President and CEO at Immunome. He was President and CEO at Morphimmune and SeaGen. He is a Board Member at Shattuck Labs and was Chairman at Tourmaline Bio.

Frazier Life Sciences Launches Callio Therapeutics, Raises $187M Series A for Multi-Payload ADC Cancer Therapy Targeting HER2 Breast Cancer

Frazier Life Sciences launched Callio Therapeutics, a Seattle and Singapore-based startup focused on multi-payload antibody-drug conjugate cancer therapies, raising $187 million in a Series A round led by Frazier. Callio’s initial therapy targets HER2-related breast cancer using licensed technology from Hummingbird Bioscience.

GeekWire's Top Stories for Oct. 13, 2024: Microsoft Layoffs, Uber's Cannabis Delivery Deal, and Musk's Twitter Workforce Cuts

The most popular tech stories on GeekWire for the week of October 13, 2024, included Microsoft's layoffs, Jeff Bezos's economic concerns, Uber's cannabis delivery partnership with Leafly, and initiatives by Bill Gates in climate technology. Other key news involved enforcement debunking misinformation in Seattle, and Elon Musk's plans to reduce Twitter's workforce significantly after acquisition.

See all 9 stories, episodes and videos about Clay Siegall.

Organizations

See all 5
  • Immunome President and CEO 2023–present · current
  • Shattuck Labs Board Member 2024–present · current
  • Tourmaline Bio Chairman 2023–2025 · past

Education

  • The George Washington University Doctor of Philosophy - PhD, Genetics
  • University of Maryland Bachelor of Science - BS, Zoology

Online